+7 (495)150-11-22 
+7 (800)250-87-00 
+7 (499)110-40-67 
![Радионуклидная терапия радия хлоридом [223Ra]](https://new.nmicr.ru/wp-content/uploads/2023/08/img_0383.jpg.webp "Радионуклидная терапия радия хлоридом [223Ra]")
Radionuclide therapy with radium chloride [223Ra]
Radium chloride [223 Ra] is used for radionuclide therapy in patients with castration-resistant prostate cancer with metastatic bone damage, usually accompanied by an increase in bone metabolism with increased mineralization. Being a chemical analog of calcium, radium chloride [223 Ra] actively accumulates in areas with increased bone mineralization, exerting a damaging effect on tumor cells. The therapeutic effect of radium chloride [223 Ra] is due to the emission of alpha particles. A high linear value of the transfer energy of α-particles (80 keV/µm) leads to a high frequency of double-stranded DNA molecule breaking and causes a strong cytotoxic effect. The range of action of radium chloride [223 Ra] alpha particles is less than 100 microns (less than ten cell diameters), which minimizes damage to healthy surrounding tissues.
To obtain the maximum therapeutic effect, it is necessary to complete a full course of radionuclide therapy with radium chloride [223 Ra], including 6 injections with an interval of 28 days. If clinically significant adverse events occur, the interval between injections can be extended to 8 weeks in order to stop them and determine the safety of continuing therapy. In addition, in the case of confirmed clinically significant progression of prostate cancer, the course of radium chloride [223 Ra] treatment may be interrupted.
![Radionuclide therapy with radium chloride [223Ra]](https://new.nmicr.ru/wp-content/uploads/2023/08/img_0388.jpg "Radionuclide therapy with radium chloride [223Ra]")
How to get radionuclide therapy with radium chloride [223 Ra]
Radionuclide therapy with radium chloride [223 Ra] at the P. A. Herzen Moscow Research Institute of Radiology, a branch of the Federal State Budgetary Institution “NMRC of Radiology” of the Ministry of Health of the Russian Federation is carried out within the framework of compulsory medical insurance or at the patient’s personal expense.
To consider the possibility of radionuclide therapy with radium chloride [223 Ra], the patient should contact the unified contact center of the Federal State Budgetary Institution “NMRC of Radiology” of the Ministry of Health of the Russian Federation by phone +7 (495) 150-11-22 and consult an oncologist.
To conduct a consultation, the patient must provide medical documentation containing up-to-date information about the treatment performed, and the results of studies performed with a limitation period of no more than 30 days at the time of treatment:
- general clinical blood test (with determination of the absolute number of neutrophils, platelets, and hemoglobin level);
- biochemical blood test (with determination of creatinine, ALT, AST levels);
- a blood test that evaluates PSA and testosterone levels;
- CT scan of the thoracic, abdominal and pelvic organs (preferably with intravenous X-ray contrast agent in the absence of contraindications) or (preferably) PET/CT with 68 Ga-PSMA or 18 F-PSMA;
- osteoscintigraphy (required on an electronic carrier in DICOM format, if necessary, it can be performed in the Department of Radionuclide Therapy and Diagnostics of the P. A. Herzen Moscow Research Institute).
If you have any questions related to radionuclide therapy with radium chloride [223 Ra], please contact the Department of Radionuclide Therapy and Diagnostics of the P. A. Herzen Moscow State Research Institute (by phone: +7 (495) 945-87-18 or by e-mail: rnt@nmicr.ru).
![Radionuclide therapy with radium chloride [223Ra]](https://new.nmicr.ru/wp-content/uploads/2023/08/30b00a35-71ff-4027-8b27-161cec59.jpg "Radionuclide therapy with radium chloride [223Ra]")
About the branch
The Department of Radionuclide Therapy and Diagnostics of the Herzen Moscow Research Institute of Radiology, a branch of the Federal State Budgetary Institution “National Research Medical Center of Radiology” of the Ministry of Health of the Russian Federation conducts research in patients with both oncological, endocrinological, urological and cardiological profiles.
A wide range of radionuclide studies is performed daily, of which a third is carried out on hybrid studies (SPECT)./CT, PET/CT scan. Expert-level consultation work is carried out, both in person and with the use of telemedicine technologies.
Doctors of the department have extensive experience in the field of radionuclide and hybrid imaging, actively participate in the scientific work of the center, are members of domestic and foreign scientific communities, and regularly make presentations on topical topics of the use of radionuclide diagnostics methods in oncology.
For patients, comfortable conditions of stay in the department are created, a favorable and friendly atmosphere is maintained by the well-coordinated work of not only doctors, but also secondary medical personnel.
